Drugs that contain Roflumilast
1. List of Daliresp drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(13 days from now) | |
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(13 days from now) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 1 month from now) | |
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 1 month from now) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 1 month from now) | |
Market Authorisation Date: 28 February, 2011
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET;ORAL
2. List of Zoryve drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(14 years from now) | |
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(14 years from now) | |
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(14 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 29, 2025 |
Market Authorisation Date: 29 July, 2022
Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)
Dosage: CREAM;TOPICAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic